eLife (Jun 2021)

Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction

  • M Ines Pascoal Ramos,
  • Linjie Tian,
  • Emma J de Ruiter,
  • Chang Song,
  • Ana Paucarmayta,
  • Akashdip Singh,
  • Eline Elshof,
  • Saskia V Vijver,
  • Jahangheer Shaik,
  • Jason Bosiacki,
  • Zachary Cusumano,
  • Christina Jensen,
  • Nicholas Willumsen,
  • Morten A Karsdal,
  • Linda Liu,
  • Sol Langermann,
  • Stefan Willems,
  • Dallas Flies,
  • Linde Meyaard

DOI
https://doi.org/10.7554/eLife.62927
Journal volume & issue
Vol. 10

Abstract

Read online

Collagens are a primary component of the extracellular matrix and are functional ligands for the inhibitory immune receptor leukocyte-associated immunoglobulin-like receptor (LAIR)-1. LAIR-2 is a secreted protein that can act as a decoy receptor by binding collagen with higher affinity than LAIR-1. We propose that collagens promote immune evasion by interacting with LAIR-1 expressed on immune cells, and that LAIR-2 releases LAIR-1-mediated immune suppression. Analysis of public human datasets shows that collagens, LAIR-1 and LAIR-2 have unique and overlapping associations with survival in certain tumors. We designed a dimeric LAIR-2 with a functional IgG1 Fc tail, NC410, and showed that NC410 increases human T cell expansion and effector function in vivo in a mouse xenogeneic-graft versus-host disease model. In humanized mouse tumor models, NC410 reduces tumor growth that is dependent on T cells. Immunohistochemical analysis of human tumors shows that NC410 binds to collagen-rich areas where LAIR-1+ immune cells are localized. Our findings show that NC410 might be a novel strategy for cancer immunotherapy for immune-excluded tumors.

Keywords